Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 open-label acalabrutinib study in Waldenström macroglobulinemia
NL-OMON53142Phase 2Completed
- Sponsor
- Acerta Pharma
- Start
- Jan 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of acalabrutinib in Waldenström macroglobulinemia (WM), sponsored by Acerta Pharma. Started Jan 2015; status: completed.
02
Drugs
acalabrutinib
03
Conditions
Waldenström macroglobulinemia (WM)
Beyond the preview
Go deeper on NL-OMON53142.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON53142.